Blackstone's bet on cell and gene therapy sends Cryoport shares skyward

For Blackstone, investing in Cryoport offers a means to ride the rapid and sustained growth of cell and gene therapy without taking on any idiosyncratic risk.

28 August 2020•4 mins read
Bain Capital, life sciences, private equity, venture capital
LinkedInXEmail
LinkedInXEmail

Related articles